PDGF antagonist, with the CAS number 143784-00-3, is a chemical compound that functions primarily as an inhibitor of platelet-derived growth factor (PDGF) signaling pathways. PDGF is a key player in various biological processes, including cell growth, proliferation, and angiogenesis. The antagonist's mechanism of action typically involves blocking the interaction between PDGF and its receptors, thereby inhibiting downstream signaling cascades that contribute to pathological conditions such as fibrosis, cancer, and vascular diseases. This compound is often studied for its potential therapeutic applications in treating diseases characterized by excessive PDGF activity. In terms of physical properties, PDGF antagonists may exhibit moderate solubility in organic solvents and variable stability under different pH conditions. Additionally, the pharmacokinetics, bioavailability, and toxicity profiles of such compounds are crucial for their development as therapeutic agents. Overall, PDGF antagonists represent a significant area of research in pharmacology and medicinal chemistry, aiming to provide targeted treatments for conditions driven by PDGF-mediated processes.

PDGF Antagonist

143784-00-3: PDGF antagonist, with the CAS number 143784-00-3, is a chemical compound that functions primarily as an inhibitor of platelet-derived growth factor (PDGF) signaling pathways. PDGF is a key player in various biological processes, including cell growth, proliferation, and angiogenesis. The antagonist's mechanism of action typically involves blocking the interaction between PDGF and its receptors, thereby inhibiting downstream signaling cascades that contribute to pathological conditions such as fibrosis, cancer, and vascular diseases. This compound is often studied for its potential therapeutic applications in treating diseases characterized by excessive PDGF activity. In terms of physical properties, PDGF antagonists may exhibit moderate solubility in organic solvents and variable stability under different pH conditions. Additionally, the pharmacokinetics, bioavailability, and toxicity profiles of such compounds are crucial for their development as therapeutic agents. Overall, PDGF antagonists represent a significant area of research in pharmacology and medicinal chemistry, aiming to provide targeted treatments for conditions driven by PDGF-mediated processes.

<p>H-Ala-Asn-Phe-Leu-Val-Trp-Glu-Ile-Val-Arg-Lys-Lys-Pro is a monoclonal antibody that inhibits proliferation of endothelial cells. It binds to PDGF, which is a potent growth factor. This drug has been shown to inhibit the growth of vascular smooth muscle cells in vitro and in vivo by inhibiting cholesterol synthesis. H-Ala-Asn-Phe-Leu-Val-Trp has also been shown to have antagonist effects on basic fibroblast growth factor and cyclic AMP, which are important mediators of choroidal neovascularization and blood vessel formation.</p>

CAS 143784-00-3

PDGF Antagonist

PDGF Antagonist

Ref: 3D-FP110333